India, June 25 -- Merck KGaA (MKKGY,MRCG.DE,MRK.DE), a German science and technology major, said on Thursday that it has inked a deal to buy Bio-Techne Corporation (TECH) for $73 per share in cash, or around $11.3 billion.
The acquisition price represents a 36% premium to Bio-Techne's one-month volume-weighted average trading price. The acquirer will fund the acquisition through a combination of cash on hand and new debt.
Bio-Techne is a provider of life science tools, analytical technologies, and consumables.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
TECH was up by 23.79% at $72.88 in the pre-market trade on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Published by HT...